|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
First published online 11 April 2007
doi: 10.1242/dev.002402
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.
* Author for correspondence (e-mail: c.ruhrberg{at}ucl.ac.uk)
Accepted 27 February 2007
| SUMMARY |
|---|
|
|
|---|
Key words: VEGF, Neuropilin, Semaphorin, Mouse
| INTRODUCTION |
|---|
|
|
|---|
VEGF164 acts in concert with two other major VEGF isoforms termed VEGF120
and VEGF188 (VEGF121 and VEGF189 in humans) to promote vascular development by
signalling through several different VEGF receptors (reviewed by
Ruhrberg, 2003
). VEGF and its
main vascular receptor, the transmembrane tyrosine kinase KDR (also known as
FLK1 and VEGFR2), are essential for the earliest stages of vascular
development in order to promote the differentiation of mesodermal precursors
into endothelial cells and their condensation into vessel networks in a
process termed vasculogenesis. Importantly, each one of the three major VEGF
isoforms is able to direct this process and is therefore able to support
embryonic development (Carmeliet et al.,
1999
; Ruhrberg et al.,
2002
; Stalmans et al.,
2002
). This is most likely to be due to the fact that each isoform
can bind KDR to control endothelial cell differentiation, proliferation and
migration (reviewed by Ruhrberg,
2003
).
By contrast, the VEGF isoforms play different roles during later stages of
vascular development. Based on a differential affinity for heparan sulphate
proteoglycans in the extracellular matrix, the isoforms cooperate to establish
chemoattractive gradients around VEGF-secreting cells and attract sprouts from
pre-existing blood vessels in a process termed angiogenesis
(Park et al., 1993
;
Ruhrberg et al., 2002
). In
this fashion, VEGF isoform expression supports the formation of microvessel
networks with optimal density and connectivity. In addition, VEGF164
signalling through NRP1 on endothelial cells is thought to contribute to
vascular growth by potentiating KDR signalling
(Soker et al., 1998
).
Consistent with this idea, endothelial cells express NRP1
(Kitsukawa et al., 1995
), and
loss of NRP1 specifically from endothelial cells impairs brain vascularisation
(Gu et al., 2003
).
Although NRP1 is essential for vascular development, it was first
identified as an adhesion protein in the central nervous system (CNS) and then
as a receptor for class 3 semaphorins, a family of secreted guidance cues for
embryonic nerves (Raper,
2000
). Loss of the archetypical class 3 semaphorin SEMA3A causes
axon defasciculation and excessive branching of several types of nerves in the
developing mouse (Taniguchi et al.,
1997
). These defects are phenocopied in mice lacking NRP1 and in
mice carrying a mutation in the a1 domain of NRP1 that is essential for
binding to class 3 semaphorins (Gu et al.,
2003
; Kitsukawa et al.,
1997
). Together, semaphorins and neuropilins also play an
essential role in heart development. Loss of semaphorin signalling through
NRP1 or NRP2 does not compromise heart development; however, when the binding
of semaphorins to NRP1 is abolished in a NRP2-null background, septation of
the heart outflow tract into an arterial and venous compartment is impaired
(Gu et al., 2003
). Similar
defects are found in mice lacking the neuropilin-ligand SEMA3C and have been
attributed to impaired guidance of cardiac neural crest cells into the outflow
tract (Feiner et al.,
2001
).
|
Several different models have been put forward to explain the role of class
3 semaphorins and NRP1 in vascular development
(Fig. 1B-F). First, it has been
suggested that SEMA3A modulates VEGF signalling by competing with VEGF164 for
binding to NRP1 (Miao et al.,
1999
) (Fig. 1B).
Second, SEMA3A might signal directly through complexes containing NRP1 and
A-type plexins in endothelial cells, as in neurons
(Fig. 1C)
(Serini and Bussolino, 2004
;
Tamagnone and Giordano, 2006
).
Third, class 3 semaphorins may influence cardiovascular development by
signalling through plexin D1-neuropilin complexes rather than plexin
A-neuropilin complexes (Fig.
1D) (Gitler et al.,
2004
; Torres-Vazquez et al.,
2004
); importantly, at least one class 3 semaphorin, SEMA3E, can
signal through plexin D1 in a mechanism that does not require NRP1
(Gu et al., 2005
)
(Fig. 1E).
Not only has SEMA3A been implicated as a modifier of VEGF164-mediated
endothelial cell growth, but the reverse situation has also been described for
neuron culture models, in which the balance of VEGF164 and SEMA3A controls the
migration and apoptosis of neuronal progenitor cells
(Bagnard et al., 2001
).
Moreover, VEGF164 has been hypothesised to act as an axonal guidance cue by
binding to NRP1 in competition with SEMA3A
(Carmeliet, 2003
)
(Fig. 1F). However, evidence
that VEGF acts as an axonal patterning factor in vivo is thus far lacking. By
contrast, VEGF164 contributes to the control of neuronal migration, as it is
essential for the cell body migration of facial branchiomotor neurons in the
mouse hindbrain (Schwarz et al.,
2004
).
To address which of the above models best describes the role of NRP1-binding semaphorins during vascular development, and to examine whether VEGF164 cooperates with SEMA3A to control axon patterning, we have compared the genetic requirements for these NRP1 ligands during axonal and vascular patterning in the mouse. Unexpectedly, we found no evidence for a competitive relationship between SEMA3A and VEGF164 during endothelial or neuronal growth; rather, NRP1-based signalling pathways display a previously unappreciated context-dependent specificity for either semaphorins or VEGF.
| MATERIALS AND METHODS |
|---|
|
|
|---|
For genotyping, genomic DNA from tissue biopsies was analysed by PCR using the Megamix Blue reaction mix (Helena BioSciences) and oligonucleotide primers specific for the gene-targeted loci.
Sema3a locus: 5'-CTGCAGACGCTGGAGGTCCCTGAG-3', 5'-CATTGTCAGCGCGTCTAGTGAGTGTTGG-3' and 5'-CTTGTAATGGTTCTGATAGGTGAGGCATGG-3';
Vegfa locus: 5'-CAGTCTATTGCCTCCTGACCTTCAGGGTG-3', 5'-CTTGCGTCCACACCGTCACATTAAGTCAC-3' and 5'-TTCAGAGCGGAGAAAGCATTTGTTTGTCCA-3';
Nrp1 locus: 5'-CGTGATATTGCTGAAGAGCTTGGC-3', 5'-CAATGACACTGACCAGGCTTATCATC-3' and 5'-GATTTTTATGGTCCCGCCACATTTGTC-3';
Nrp2 locus: 5'-CAGTGACAACGTCGAGCACAG-3', 5'-TCAGGACACGAAGTGAGAAGC-3' and 5'-GCTCAATGTAGCTAAGTGGAGGG-3';
Nrp1sema-/- mutation: 5'-AGGCCAATCAAAGTCCTGAAAGACAGTCCC-3' and 5'-AAACCCCCTCAATTGATGTTAACACAGCCC-3'.
Alkaline phosphatase-fusion protein-binding assay
Expression vectors encoding secreted alkaline phosphatase (AP) or the
fusion proteins AP-SEMA3A, AP-SEMA3C, AP-SEMA3E, AP-SEMA3F or AP-VEGF165
(kindly provided by Drs J. A. Epstein and J. A. Raper, School of Medicine,
University of Pennsylvania, Philadelphia, PA) were transfected into HEK-293T
cells using FuGENE6 (Roche). Serial dilutions of medium containing AP-fusion
proteins were spotted onto nitrocellulose filters, and relative AP activity
was determined by incubation with nitroblue tetrazolium (NBT) and
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) (Roche) in a buffer containing 100
mM Tris pH 9.5, 100 mM NaCl, 5 mM MgCl2. For whole-mount AP assays,
freshly dissected 11.5 dpc hindbrain tissue was incubated in PBS containing
0.1% Triton X-100 (PBT) and 10% foetal bovine serum for 30 minutes prior to
reaction with an appropriate dilution of conditioned medium containing
AP-fusion protein for 2 hours at room temperature. Tissues were then washed
three times for 20 minutes each with PBT, fixed with 4% formaldehyde for 1
hour at room temperature, and washed again. Endogenous AP was heat-inactivated
at 65°C for 3 hours. Tissue-bound heat-stable recombinant AP activity was
detected as an insoluble reaction product after incubation with NBT and BCIP
as described above. Images were recorded using a MZ16 microscope (Leica)
equipped with a ProgRes C14 digital camera (Jenoptiks, Jena, Germany) and
OpenLab 3.5.1 software (Improvision).
Immunohistochemistry
Freshly dissected tissue was fixed for 2 hours in 4% formaldehyde,
transferred to PBS, then 50% methanol in PBS, and then methanol for 5 minutes
each and stored in methanol until use. For immunohistochemistry, samples were
rehydrated and endogenous peroxidase activity quenched with 0.1% hydrogen
peroxide in PBS for 30 minutes at room temperature. After washing twice in
PBT, samples were incubated for 2 hours in blocking solution (PBT containing
10% normal rabbit or goat serum, depending on the secondary antibody used) and
then overnight at 4°C in primary antibody diluted in blocking solution.
Blood vessels were detected with rat anti-PECAM (also known as PECAM1 and
CD31) (BD Pharmingen) or rat anti-endomucin antibodies (gift of Dr D.
Vestweber, University of Muenster, Germany). The heart was visualised with
mouse anti-smooth muscle actin antibody (Sigma), nerves with rabbit
anti-neurofilament antibodies (Chemicon). Samples were washed five times for 1
hour each in PBT at room temperature and then incubated overnight at 4°C
with secondary antibodies in blocking solution. Secondary antibodies used were
horseradish peroxidase-conjugated rabbit anti-rat IgG or goat anti-rabbit IgG
(Dako), and Alexa488-conjugated goat anti-rat IgG, Alexa543-conjugated goat
anti-rabbit IgG or Alexa543-conjugated anti-mouse IgG (Molecular Probes).
Samples were washed as described above and fixed for 30 minutes (4%
formaldehyde in PBS) or developed with diaminobenzidine and hydrogen peroxide
(SigmaFast; Sigma) and then fixed. Alexa-labelled samples were mounted on
glass slides using SlowFade (Molecular Probes) and analysed with a LSM510
laser scanning confocal microscope (Zeiss). Images from horseradish
peroxidase-labelled samples were recorded using the MZ16 microscope as
described above.
Quantitation of vessel and nerve density
To quantify vessel branching in the subventricular vessel plexus, 12.5 dpc
PECAM-stained hindbrains of different genotypes were flat-mounted under glass
coverslips and photographed at the same magnification. For each sample, the
number of branchpoints was determined in three randomly chosen 0.25
mm2 regions; error bars represent the standard deviation from the
mean. For each mutant genotype, between five and 13 samples from at least
three different matings were analysed, with the exception of the
Nrp1sema-/- Nrp2-/- double-mutant genotype
(n=3). To quantify the branching of sensory nerves in the limb, we
mounted neurofilament-stained limbs at 13.5 dpc under glass coverslips and
counted the number of nerve branchpoints in the area corresponding to the
future footplate.
| RESULTS |
|---|
|
|
|---|
SEMA3A is not required for the formation of the large axial vessels in the mouse
Because SEMA3A binds to developing vessels and has been implicated in
endothelial cell migration, we asked whether it controls vascular development.
We initially examined embryos lacking SEMA3A at 9.5 and 10.5 dpc, a time when
the major axial vessels have formed and vascular networks have begun to extend
throughout the body. Using two different markers for the developing
vasculature, endomucin and PECAM (Albelda
et al., 1991
; Brachtendorf et
al., 2001
), we unexpectedly found that the vasculature of null
mutants was indistinguishable from that of stage-matched wild-type littermates
in both C57Bl/6 and CD1 backgrounds (Fig.
3 and data not shown). Specifically, vascular remodelling appeared
normal in the head in 5/5 and 11/11 cases in the C57Bl/6 and CD1 backgrounds,
respectively; moreover, a paired dorsal aorta and anterior cardinal vein was
present in all cases (compare Fig. 3A with
B, and G with H). In the trunk, intersomitic vessels were present
at 9.5 dpc in all cases examined (Fig.
3C,D), and these had branched laterally by 10.5 dpc in 6/6 CD1
mutants examined (Fig. 3E,F).
At both developmental stages, the heart and pharyngeal arch arteries appeared
grossly normal. Taken together, our results suggest that SEMA3A is not
required for the formation of the major axial vessels, vessel branching or
vessel remodelling in either the C57Bl/6 or CD1 background at 9.5 dpc. Our
findings contrast with those of Serini and co-workers, who recently described
defects in all these regions at 9.5 dpc in SEMA3A-null mutants in the CD1 (but
not C57Bl/6) background (Serini et al.,
2003
). To confirm that our mutants had the correct genotype, we
examined their nerve patterning in addition to undertaking the usual molecular
genotyping. In agreement with previously published observations, we found that
loss of SEMA3A caused axon defasciculation in both CD1 and C57Bl/6 backgrounds
(compare Fig. 3I with J; see
also limb analysis below).
|
|
|
|
|
|
To address whether SEMA3A is able to influence endothelial cell migration in mutants with reduced VEGF164 levels ('backup role'), we studied vessel branching in the hindbrain. Loss of SEMA3A did not alter the defect caused by loss of the heparin/neuropilin-binding VEGF isoforms (Fig. 7). First, we examined the role of SEMA3A in vessel branching when the level of VEGF120 was higher than that of VEGF164 (10 cases; compare Fig. 7B with E). Then we examined the role of SEMA3A in vessel branching when VEGF164 expression was completely abolished (5 cases; compare Fig. 7C with F). In all instances in which VEGF164 levels were lower than VEGF120 levels, the mesh size of vessel networks was reduced independently of SEMA3A, i.e. vessel networks appeared similar in Vegfa mutants expressing or lacking SEMA3A (compare Fig. 7A-C with D-F). Moreover, there was no difference in the amount of vessel branching in the presence or absence of SEMA3A (Fig. 7G). The observation that loss of SEMA3A does not affect the phenotype caused by loss of heparin/neuropilin-binding VEGF isoforms during vasculogenesis or angiogenesis suggests that there is no genetic interaction between Vegfa and Sema3a during vessel development in the mouse.
|
To address whether the competition between VEGF164 and SEMA3A for NRP1 binding previously observed in vitro contributes to neurovascular development, we compared the vascular limb phenotype of mouse mutants lacking VEGF164 in the presence or absence of SEMA3A, and the axonal phenotype of SEMA3A mutants in the presence or absence of VEGF164, by examining compound mutants lacking both NRP1 ligands (Figs 8, 9). We found that the absence of SEMA3A neither rescued nor worsened the vessel defect of limbs lacking VEGF164 in 4/4 embryos examined (compare Fig. 9C with D, and H with I). Vice versa, the loss of VEGF164 did not alter the axon branching defect caused by loss of SEMA3A (compare Fig. 8B with D). These observations imply that VEGF164/NRP1 signalling specifically controls vascular development, whereas SEMA3A/NRP1 signalling specifically controls axonal patterning in the limb. Consistent with the idea of an exclusive functional specialisation of both NRP1 ligands during neurovascular patterning in the developing limb, only mutants lacking both VEGF164 and SEMA3A displayed defects in both vascular and axonal limb patterning, similar to those seen in NRP1 mutants (compare Fig. 8D,I with E,J, and Fig. 9D,I with E,J).
|
| DISCUSSION |
|---|
|
|
|---|
Our findings contrast with those of Serini and co-workers, who described
dramatic vascular defects at 9.5 dpc in SEMA3A-null mutants in the CD1
background (Serini et al.,
2003
). The discrepancy between our results and theirs was
surprising, given that Serini and co-workers have analysed mice carrying the
same gene-targeting event that we examined
(Taniguchi et al., 1997
). The
lack of a vascular phenotype in our analysis of SEMA3A-null mutants was
particularly clear in the developing brain, where the quantitative analysis of
vessel branching confirmed that a similar number of microvessels was present
in wild-type and mutant littermates. Importantly, the number of vessel
branches was more variable in the CD1 as compared with the C57Bl/6 background,
as expected from an outbred genetic background (e.g.
Chia et al., 2005
), but
variability was similar for all genotypes analysed (compare error bars for
both backgrounds in Fig.
4G).
The developmental variability in the CD1 background was particularly obvious at younger gestational ages; for example, we found that the somite number of wild-type embryos within a CD1 litter at 9.5 dpc varied from 19 to 24 (see Fig. S1 in the supplementary material). We therefore always compared embryos that were age-matched (i.e. of the same gestational age) as well as stage-matched (for example, by comparing somite number at 9.5 dpc). The greater variability of vessel branching, and even embryo size within a litter, might have contributed to the conclusion of Serini and co-workers that vascular patterning is abnormal in Sema3a-null mutants in the outbred CD1 strain.
In addition, a less robust method of sample analysis might have contributed
to the conclusion of Serini and co-workers that formation of the anterior
cardinal vein was impaired. To detect the anterior cardinal vein at 9.5 dpc,
Serini and co-workers performed whole-mount immunohistochemistry with
anti-PECAM and horseradish peroxidase-conjugated secondary antibodies and
recorded the image using a conventional light microscope
(Serini et al., 2003
). Using
this method to examine six littermate wild-type embryos at 9.5 dpc, we
detected the anterior cardinal vein in 3/6 embryos on the left or right side
only (see Fig. S2 in the supplementary material); in 2/6 cases, the anterior
cardinal vein was not detectable on any side, and in 1/6 cases it was visible
on both sides of the embryo (not shown). Subsequent dissection revealed that a
paired cardinal vein had been present in all these cases. When we used
antibodies to PECAM or endomucin and recorded images by laser scanning
confocal microscopy, we were able to identify the anterior cardinal vein on
both embryonic sides in 40/40 whole-mount-stained CD1 embryos at 9.5 dpc
without the need to section the samples (compare Fig. S1 with Fig. S2 in the
supplementary material; see also Figs
3 and
6). We therefore conclude that
laser scanning confocal microscopy is superior to light microscopy for
detecting the anterior cardinal vein in whole-mount samples at 9.5 dpc. We
also found that endomucin was a superior marker to PECAM for the detection of
the vasculature at 9.5 dpc, when blood vessels are relatively more immature
than at later developmental stages: whereas blood vessels stained weakly with
anti-PECAM antibodies at 9.5 dpc (see Fig. S2 in the supplementary material),
blood vessels stained robustly with the same antibodies at 10.5 and 12.5 dpc
(see Figs 3 and
4).
Lastly, we cannot exclude the possibility that unknown genetic modifiers have been introduced in either our or their laboratory during backcrossing of SEMA3A C57/Bl6 mice into the CD1 background. For this reason, we extended our analysis to an independently derived line of CD1 SEMA3A mice, but again found none of the previously described vascular defects (J.M.V. and C.R., unpublished).
In a complementary approach, we found that semaphorin signalling through
neuropilins was not required for microvessel patterning in the brain and limb
(Fig. 5 and data not shown).
Our results therefore agree with those of Gu and co-workers, who did not
observe vessel defects in mice lacking semaphorin signalling through
neuropilins at earlier developmental stages
(Gu et al., 2005
). In further
support of the idea that semaphorin signalling through neuropilins is not
required for the patterning of vascular endothelium, plexin A2, A3 and A4 are
all dispensable for vascular development (Q.S., C.R., K. Waimey, H. J. Cheng
and H. Fujisawa, unpublished), even though they are essential co-receptors for
semaphorin signalling through neuropilins in neurons (reviewed by
Fujisawa, 2004
). Moreover,
mice lacking both SEMA3A (which binds NRP1) and SEMA3C (which binds NRP1 and
NRP2) show normal brain vascularisation (Q.S., J.M.V., C.R. and K. Sabelko,
unpublished).
|
VEGF and axon guidance
Based on the finding that SEMA3A and VEGF164 compete for NRP1 binding in
vitro, it has been hypothesised that VEGF164 controls axon guidance, either
directly or in competition with SEMA3A
(Carmeliet, 2003
). However, we
have previously shown that SEMA3A, but not VEGF164, controls the behaviour of
cranial nerve axons (Schwarz et al.,
2004
) (see also Fig.
3). We now extend this finding to include limb nerves (Figs
8 and
10). Moreover, we show that
the competitive model of VEGF164 and SEMA3A described in
Fig. 1F is unlikely to be
relevant for axonal patterning (Figs
8 and
10). Although our observations
suggest that VEGF164 does not play a general role in axon guidance of
NRP1-expressing nerves in the peripheral nervous system, we cannot exclude the
possibility that VEGF164 plays a role in axon guidance within the CNS, as it
is able to bind to axon tracts in the hindbrain
(Fig. 2G). It might be
informative to identify NRP1-expressing CNS neurons whose axons are not
normally guided by SEMA3A, so as to study their functional requirement for
VEGF164, as there appears to exist a mutually exclusive use of either NRP1
ligand. The concept of preferential use of either VEGF164 or SEMA3A by
different cell types is not only evident during axonal and vascular patterning
in the developing limb and branchial arches, but also in the case of the
facial branchiomotor neurons, which use SEMA3A for axon guidance and VEGF164
to position their cell bodies (Schwarz et
al., 2004
).
Cooperation, not competition, of NRP1 ligands during neurovascular development
Neurovascular co-patterning, as exemplified by the innervation of major
arteries and the presence of the vasa nervosum, has recently become a topic of
intense interest. NRP1 and its ligands have been considered plausible
candidates to coordinate the association of vessels and nerves. Based on
experiments with chick limbs carrying SEMA3A implants, it has been proposed
that vessels and nerves are both repelled by SEMA3A signals emanating from the
prechondrogenic mesenchyme in a mechanism requiring NRP1, and that this
mechanism contributes to the emergence of neurovascular congruence
(Bates et al., 2003
). Although
our observations are consistent with a role for NRP1 in controlling the
vascularisation of areas surrounding the cartilage anlagen for the digits, we
did not identify any vascular defects in SEMA3A mutants in these regions at
12.5 dpc (Figs 8 and
9). Rather, vascular
development in the limb appeared to be controlled by VEGF. Moreover, the
reduced vessel branching in limbs lacking VEGF164 did not obviously affect
nerve patterning (Fig. 10).
Taken together, these findings imply that the competition between SEMA3A and
VEGF164 for NRP1 binding does not provide the basis for the striking
neurovascular congruence seen in the mouse limb at later developmental stages.
However, we would like to point out that slight vascular overgrowth occurs in
areas of excess nerve growth after 13.5 dpc in SEMA3A mutants (data not
shown), which is likely to be caused by VEGF secretion from ectopic limb
nerves (Mukouyama et al.,
2005
).
Context-dependent ligand selectivity of NRP1-based signalling pathways
The observation that SEMA3A and VEGF164 control mutually exclusive
patterning events suggests that NRP1-based signalling pathways display
context-dependent ligand selectivity. Such selectivity may be achieved by
different means. For example, it is conceivable that NRP1 binds VEGF164 and
SEMA3A with different specificity in the presence of different co-factors on
the cell surface. However, the hindbrain model suggests that VEGF164 and
SEMA3A both bind axons and endothelial cells
(Fig. 2). Alternatively,
VEGF164 and SEMA3A might bind NRP1 on vessels and neurons independently of
specific co-factors on the cell surface, but induce distinct conformational
changes in NRP1 that selectively activate VEGFR2 or A-type plexins,
respectively, or activate different downstream signalling pathways, because
specific co-receptors such as VEGFR2 or A-type plexins are not present in one
or the other cell type. As we have not been able to detect A-type plexins in
brain endothelial cells or VEGFR2 in embryonic spinal motor/sensory neurons in
situ (J.M.V., Q.S. and C.R, unpublished), we favour the latter possibility.
Importantly, the specificity of these NRP1-based signalling pathways may be
lost under conventional cell culture conditions, in pathological angiogenesis
or in cancer, perhaps because of abnormal co-factor expression profiles.
Future work should therefore aim to identify the factors that control the
selective usage of different NRP1 ligands during neuronal and vascular
development.
Supplementary material
Supplementary material for this article is available at
http://dev.biologists.org/cgi/content/full/134/10/1833/DC1
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Albelda, S. M., Muller, W. A., Buck, C. A. and Newman, P. J.
(1991). Molecular and cellular properties of PECAM-1
(endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J.
Cell Biol. 114,1059
-1068.
Bagnard, D., Vaillant, C., Khuth, S. T., Dufay, N., Lohrum, M.,
Puschel, A. W., Belin, M. F., Bolz, J. and Thomasset, N.
(2001). Semaphorin 3A-vascular endothelial growth factor-165
balance mediates migration and apoptosis of neural progenitor cells by the
recruitment of shared receptor. J. Neurosci.
21,3332
-3341.
Bates, D., Taylor, G. I., Minichiello, J., Farlie, P., Cichowitz, A., Watson, N., Klagsbrun, M., Mamluk, R. and Newgreen, D. F. (2003). Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. Dev. Biol. 255,77 -98.[CrossRef][Medline]
Behar, O., Golden, J. A., Mashimo, H., Schoen, F. J. and Fishman, M. C. (1996). Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383,525 -528.[CrossRef][Medline]
Brachtendorf, G., Kuhn, A., Samulowitz, U., Knorr, R., Gustafsson, E., Potocnik, A. J., Fassler, R. and Vestweber, D. (2001). Early expression of endomucin on endothelium of the mouse embryo and on putative hematopoietic clusters in the dorsal aorta. Dev. Dyn. 222,410 -419.[CrossRef][Medline]
Carmeliet, P. (2003). Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev. Genet. 4,710 -720.[CrossRef][Medline]
Carmeliet, P., Ng, Y. S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen, I., Ehler, E., Kakkar, V. V., Stalmans, I., Mattot, V. et al. (1999). Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495-502.[CrossRef][Medline]
Chia, R., Achilli, F., Festing, M. F. and Fisher, E. M. (2005). The origins and uses of mouse outbred stocks. Nat. Genet. 37,1181 -1186.[CrossRef][Medline]
Chilton, J. K. and Guthrie, S. (2003). Cranial expression of class 3 secreted semaphorins and their neuropilin receptors. Dev. Dyn. 228,726 -733.[CrossRef][Medline]
Cleaver, O. and Krieg, P. A. (1998). VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. Development 125,3905 -3914.[Abstract]
Eichmann, A., Makinen, T. and Alitalo, K.
(2005). Neural guidance molecules regulate vascular remodeling
and vessel navigation. Genes Dev.
19,1013
-1021.
Feiner, L., Webber, A. L., Brown, C. B., Lu, M. M., Jia, L., Feinstein, P., Mombaerts, P., Epstein, J. A. and Raper, J. A. (2001). Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development 128,3061 -3070.[Medline]
Fujisawa, H. (2004). Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J. Neurobiol. 59,24 -33.[CrossRef][Medline]
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C.,
Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima,
D. et al. (2003). VEGF guides angiogenic sprouting utilizing
endothelial tip cell filopodia. J. Cell Biol.
161,1163
-1177.
Gerhardt, H., Ruhrberg, C., Abramsson, A., Fujisawa, H., Shima, D. and Betsholtz, C. (2004). Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev. Dyn. 231,503 -509.[CrossRef][Medline]
Gitler, A. D., Lu, M. M. and Epstein, J. A. (2004). PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Dev. Cell 7,107 -116.[CrossRef][Medline]
Gu, C., Limberg, B. J., Whitaker, G. B., Perman, B., Leahy, D.
J., Rosenbaum, J. S., Ginty, D. D. and Kolodkin, A. L.
(2002). Characterization of neuropilin-1 structural features that
confer binding to semaphorin 3A and vascular endothelial growth factor 165.
J. Biol. Chem. 277,18069
-18076.
Gu, C., Rodriguez, E. R., Reimert, D. V., Shu, T., Fritzsch, B., Richards, L. J., Kolodkin, A. L. and Ginty, D. D. (2003). Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5, 45-57.[CrossRef][Medline]
Gu, C., Yoshida, Y., Livet, J., Reimert, D. V., Mann, F., Merte,
J., Henderson, C. E., Jessell, T. M., Kolodkin, A. L. and Ginty, D. D.
(2005). Semaphorin 3E and plexin-D1 control vascular pattern
independently of neuropilins. Science
307,265
-268.
Hafezparast, M., Klocke, R., Ruhrberg, C., Marquardt, A.,
Ahmad-Annuar, A., Bowen, S., Lalli, G., Witherden, A. S., Hummerich, H.,
Nicholson, S. et al. (2003). Mutations in dynein link motor
neuron degeneration to defects in retrograde transport.
Science 300,808
-812.
Ito, T., Kagoshima, M., Sasaki, Y., Li, C., Udaka, N., Kitsukawa, T., Fujisawa, H., Taniguchi, M., Yagi, T., Kitamura, H. et al. (2000). Repulsive axon guidance molecule Sema3A inhibits branching morphogenesis of fetal mouse lung. Mech. Dev. 97,35 -45.[CrossRef][Medline]
Kawasaki, T., Kitsukawa, T., Bekku, Y., Matsuda, Y., Sanbo, M., Yagi, T. and Fujisawa, H. (1999). A requirement for neuropilin-1 in embryonic vessel formation. Development 126,4895 -4902.[Abstract]
Kessler, O., Shraga-Heled, N., Lange, T., Gutmann-Raviv, N.,
Sabo, E., Baruch, L., Machluf, M. and Neufeld, G. (2004).
Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer
Res. 64,1008
-1015.
Kitsukawa, T., Shimono, A., Kawakami, A., Kondoh, H. and Fujisawa, H. (1995). Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121,4309 -4318.[Abstract]
Kitsukawa, T., Shimizu, M., Sanbo, M., Hirata, T., Taniguchi, M., Bekku, Y., Yagi, T. and Fujisawa, H. (1997). Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 19,995 -1005.[CrossRef][Medline]
Lee, C. C., Kreusch, A., McMullan, D., Ng, K. and Spraggon, G. (2003). Crystal structure of the human neuropilin-1 b1 domain. Structure 11,99 -108.[Medline]
Mamluk, R., Gechtman, Z., Kutcher, M. E., Gasiunas, N.,
Gallagher, J. and Klagsbrun, M. (2002). Neuropilin-1 binds
vascular endothelial growth factor 165, placenta growth factor-2, and heparin
via its b1b2 domain. J. Biol. Chem.
277,24818
-24825.
Miao, H. Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A.
and Klagsbrun, M. (1999). Neuropilin-1 mediates
collapsin-1/semaphorin III inhibition of endothelial cell motility: functional
competition of collapsin-1 and vascular endothelial growth factor-165.
J. Cell Biol. 146,233
-242.
Mukouyama, Y. S., Gerber, H. P., Ferrara, N., Gu, C. and
Anderson, D. J. (2005). Peripheral nerve-derived VEGF
promotes arterial differentiation via neuropilin 1-mediated positive feedback.
Development 132,941
-952.
Park, J. E., Keller, G. A. and Ferrara, N. (1993). The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4,1317 -1326.[Abstract]
Raper, J. A. (2000). Semaphorins and their receptors in vertebrates and invertebrates. Curr. Opin. Neurobiol. 10,88 -94.[CrossRef][Medline]
Ruhrberg, C. (2003). Growing and shaping the vascular tree: multiple roles for VEGF. BioEssays 25,1052 -1060.[CrossRef][Medline]
Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou,
S., Fujisawa, H., Betsholtz, C. and Shima, D. T. (2002).
Spatially restricted patterning cues provided by heparin-binding VEGF-A
control blood vessel branching morphogenesis. Genes
Dev. 16,2684
-2698.
Schwarz, Q., Gu, C., Fujisawa, H., Sabelko, K., Gertsenstein,
M., Nagy, A., Taniguchi, M., Kolodkin, A. L., Ginty, D. D., Shima, D. T. et
al. (2004). Vascular endothelial growth factor controls
neuronal migration and cooperates with Sema3A to pattern distinct compartments
of the facial nerve. Genes Dev.
18,2822
-2834.
Serini, G. and Bussolino, F. (2004). Common cues in vascular and axon guidance. Physiology Bethesda 19,348 -354.[CrossRef][Medline]
Serini, G., Valdembri, D., Zanivan, S., Morterra, G., Burkhardt, C., Caccavari, F., Zammataro, L., Primo, L., Tamagnone, L., Logan, M. et al. (2003). Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424,391 -397.[CrossRef][Medline]
Shoji, W., Isogai, S., Sato-Maeda, M., Obinata, M. and Kuwada,
J. Y. (2003). Semaphorin3a1 regulates angioblast migration
and vascular development in zebrafish embryos.
Development 130,3227
-3236.
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. and Klagsbrun, M. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92,735 -745.[CrossRef][Medline]
Stalmans, I., Ng, Y. S., Rohan, R., Fruttiger, M., Bouche, A., Yuce, A., Fujisawa, H., Hermans, B., Shani, M., Jansen, S. et al. (2002). Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109,327 -336.[CrossRef][Medline]
Steffensky, M., Steinbach, K., Schwarz, U. and Schlosshauer, B. (2006). Differential impact of semaphorin 3E and 3A on CNS axons. Int. J. Dev. Neurosci. 24, 65-72.[CrossRef][Medline]
Tamagnone, L. and Giordano, S. (2006). Semaphorin pathways orchestrate osteogenesis. Nat. Cell Biol. 8,545 -547.[CrossRef][Medline]
Taniguchi, M., Yuasa, S., Fujisawa, H., Naruse, I., Saga, S., Mishina, M. and Yagi, T. (1997). Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 19,519 -530.[CrossRef][Medline]
Torres-Vazquez, J., Gitler, A. D., Fraser, S. D., Berk, J. D., Pham, V. N., Fishman, M. C., Childs, S., Epstein, J. A. and Weinstein, B. M. (2004). Semaphorin-plexin signaling guides patterning of the developing vasculature. Dev. Cell 7, 117-123.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
Q. Schwarz, C. H. Maden, K. Davidson, and C. Ruhrberg Neuropilin-mediated neural crest cell guidance is essential to organise sensory neurons into segmented dorsal root ganglia Development, June 1, 2009; 136(11): 1785 - 1789. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Eshkar-Oren, S. V. Viukov, S. Salameh, S. Krief, C.-d. Oh, H. Akiyama, H.-P. Gerber, N. Ferrara, and E. Zelzer The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf Development, April 15, 2009; 136(8): 1263 - 1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Schwarz, C. H. Maden, J. M. Vieira, and C. Ruhrberg Neuropilin 1 signaling guides neural crest cells to coordinate pathway choice with cell specification PNAS, April 14, 2009; 106(15): 6164 - 6169. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, and P. Carmeliet Role and Therapeutic Potential of VEGF in the Nervous System Physiol Rev, April 1, 2009; 89(2): 607 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Larrivee, C. Freitas, S. Suchting, I. Brunet, and A. Eichmann Guidance of Vascular Development: Lessons From the Nervous System Circ. Res., February 27, 2009; 104(4): 428 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kawamura, X. Li, K. Goishi, L. A. van Meeteren, L. Jakobsson, S. Cebe-Suarez, A. Shimizu, D. Edholm, K. Ballmer-Hofer, L. Kjellen, et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization Blood, November 1, 2008; 112(9): 3638 - 3649. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varshavsky, O. Kessler, S. Abramovitch, B. Kigel, S. Zaffryar, G. Akiri, and G. Neufeld Semaphorin-3B Is an Angiogenesis Inhibitor That Is Inactivated by Furin-Like Pro-Protein Convertases Cancer Res., September 1, 2008; 68(17): 6922 - 6931. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. V. Jones, L. Yuan, C. Breant, R. J. Watts, and A. Eichmann Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos Development, July 15, 2008; 135(14): 2479 - 2488. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Serini, L. Napione, M. Arese, and F. Bussolino Besides adhesion: new perspectives of integrin functions in angiogenesis Cardiovasc Res, May 1, 2008; 78(2): 213 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors Cancer Res., April 1, 2008; 68(7): 2301 - 2311. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||